Yes, that last highlighted text is very important. For the pretreatment, I’m not sure. I was referring to the mice, from the pictures, start with the cancer not spread throughout the body, it is still isolated, i.e. the ctc numbers are original 0 in the mice experiment, and leronlimab keeps them at 0. With mTNBC, they are starting with cancer already spread and ctc>0. So that experiment would indicate taking leonlimab even before the metastasis starts. I get why they went with mTNBC, faster approval. But ccr5 does more that stopping the cancer spreading initially, it helps guides the cancer to the bones and organs, and helps they new cancer sites take hold. The preclinical trial is only testing the first item. The additional work RP showed great results, starting leonlimab at a later stage, they should do a full experiment showing the full power of leronlimab.